Find Clinical Trials

FIND URTICARIA clinical trials near you

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

Interventional
Start Date: November 15, 2023
End Date: August 18, 2025
32 days until trial ends

Chronic Ideopathic Urticaria
Chronic spontaneous urticaria
Chronic Urticaria
CSU
Spontaneous Urticaria
Urticaria

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Interventional
Start Date: December 7, 2023
End Date: March 30, 2026
256 days until trial ends

CIndU
Cholinergic Urticaria
Chronic Inducible Urticaria
Chronic Urticaria
Cold Urticaria
Symptomatic Dermographism
Urticaria

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants from Jasper-Sponsored Chronic Urticaria Trials

Interventional
Start Date: November 26, 2024
End Date: December 1, 2025
137 days until trial ends

CIndU
Chronic Ideopathic Urticaria
Chronic Inducible Urticaria
Chronic spontaneous urticaria
Chronic Urticaria
CSU
Cold Urticaria
Spontaneous Urticaria
Symptomatic Dermographism
Urticaria

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

Interventional
Start Date: January 2, 2025
End Date: December 1, 2025
137 days until trial ends

Chronic Ideopathic Urticaria
Chronic spontaneous urticaria
Chronic Urticaria
CSU
Spontaneous Urticaria
Urticaria

Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU) (BEACON)

Interventional
Start Date: September 29, 2023
End Date: April 1, 2026
258 days until trial ends

Chronic Ideopathic Urticaria
Chronic spontaneous urticaria
Chronic Urticaria
CSU
Spontaneous Urticaria
Urticaria

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Interventional
Start Date: July 11, 2023
End Date: November 20, 2025
126 days until trial ends

Chronic Ideopathic Urticaria
Chronic spontaneous urticaria
Chronic Urticaria
CSU
Spontaneous Urticaria
Urticaria

Endeavor Health

United States